This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Free Reports

Rethinking Idenix Pharma in Wake of Bristol's Hep C Blow Up

The two Hep C drugs are similar enough chemically to warrant caution.

Gilead Sciences Firing On All Cylinders
Gilead Sciences Firing On All Cylinders

07/30/12 - 07:00 AM EDT

Gilead posted strong second-quarter earnings and is moving ahead aggressively with its new hepatitis C drugs.

The Health Care Short Sales That Never Fit

Valuation shorts can be investment quicksand, explains TheStreet columnist Nate Sadeghi.

Eli Lilly, Verastem and the Defenders of Shareholder Value

TheStreet contributor Nate Sadeghi calls for healthcare investors to start acting like owners.

Onyx Pharma Must Start Delivering Profits

With a second cancer drug approval looming, Onyx can join a select group of successful and profitable biotech companies.

ObamaCare Upheld: Health Care Stock Winners and Losers

TheStreet's Nathan Sadeghi-Nejad examines which health care stocks benefit from the Supreme Court's decision to uphold health care reform.

Arena Pharma And The Fat Lady's Song
Arena Pharma And The Fat Lady's Song

06/25/12 - 11:13 AM EDT

Advice to lorcaserin bulls: Cherish the moment but sell Arena, says TheStreet contributor Nate Sadeghi.

Alkermes Needs to Build on Drug Delivery Success

An undervalued stock could move higher if Alkermes continues to grow through acquisitions.

A Reckoning Approaches: Supreme Court and Obama's Healthcare Reform Law

Six possible outcomes of the Court's healthcare ruling and what it means for healthcare stocks.

Bad Romance: Glaxo's Brutal Courtship of Human Genome Sciences

Contributor Nathan Sadeghi-Nejad offers tips to Glaxo's CEO on how to woo the stubborn HGSI into marriage.

Page 3 of 5
Top Rated Stocks Top Rated Funds Top Rated ETFs